DexCom beats Q3 top and bottom line, guides FY revenue
DexCom press release  (NASDAQ:DXCM): Q3  Non-GAAP EPS of $0.28  beats by $0.04.
Revenue of $769.6M (+18.4% Y/Y)  beats by $18.56M.
Gross Profit: Gross profit totaled $494.2 million or 64.2% of revenue for the third quarter of 2022.
Â As of September 30, 2022, Dexcom held $2.37 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn.

2022 Guidance:Â Revenue of approximately $2.88 - 2.91 billion (18-19% reported growth) (vs. consensus $2.89B)
Non-GAAP Gross Profit Margin of approximately 64%
Non-GAAP Operating Margin of approximately 16%
Adjusted EBITDA Margin of approximately 25%